News for Healthier Living

Immune Drug Anifrolumab Linked to Lower Risk of Infection and Hospitalization for Skin Lupus

Preliminary results from an investigator-initiated single-site clinical study show that some people with chronic cutaneous lupus erythematosus -- a type of lupus that can cause permanent skin damage and hair loss -- are less likely to acquire life-threatening infections when taking the drug anifrolumab, an FDA-approved monoclonal antibody treatment for systemic lupus erythematosus.

September 2, 2026


September 3 2026

September 2 2026

September 1 2026

August 31 2026

August 30 2026

August 29 2026

August 28 2026

August 27 2026

August 26 2026

August 25 2026

August 24 2026

August 21 2026

August 20 2026